Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: borredo

While I'm all for a much higher share price, I don't actually see it being P/E based. The problem that the market has with a valuation on PTSC now will be the same until there are further independent revenue streams.  There is no way to accurately assess what future license fees will bring to the table. As has been stated, a Company with a billion dollar turnover might only have minimal use of the patented technology. Conversely, a company with revenue of $100 million might be totally dependent on the MMP Portfolio.

It is known that there are approximately 220 companies in discussions, and 30 companies in advanced negotiations. I would expect all of these to settle with one year of the J's settling, with the 30 settling within 6 - 8 weeks of any J settlement.

For the sake of argument, give PTSC $1 billion from the above license fees, $2.50 per share, now what? Will there be the same or greater revenue in each of the the subsequent years from licensing? If the fees weren't one-off, a predictable annual income from the licensees could be factored to use a P/E ratio, with one-off payments it becomes mere guesswork and impossible to assign the correct multiplier.

 

 

 

Be well

 

 

Share
New Message
Please login to post a reply